Arsenic trioxide
- Generic Name
- Arsenic trioxide
- Brand Names
- Trisenox, Arsenic trioxide Accord, Arsenic trioxide Mylan, Arsenic trioxide medac
- Drug Type
- Small Molecule
- Chemical Formula
- As2O3
- CAS Number
- 1327-53-3
- Unique Ingredient Identifier
- S7V92P67HO
- Background
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredo...
- Indication
For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
- Associated Conditions
- Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia, Relapsed Acute Promyelocytic Leukemia
- Associated Therapies
- -
Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment
- Conditions
- First Posted Date
- 2004-03-16
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00006091
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease
- Conditions
- First Posted Date
- 2004-03-04
- Last Posted Date
- 2012-06-11
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 2
- Registration Number
- NCT00005595
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2012-06-11
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 11
- Registration Number
- NCT00005795
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-01-12
- Last Posted Date
- 2013-02-12
- Target Recruit Count
- 30
- Registration Number
- NCT00075426
- Locations
- 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer
- Conditions
Arsenic Trioxide in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2004-01-08
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- CTI BioPharma
- Registration Number
- NCT00017433
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Scripps Clinic, La Jolla, California, United States
Arsenic Trioxide in Treating Patients With Urothelial Cancer
- First Posted Date
- 2003-12-31
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00009867
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2003-11-05
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00006008
- Locations
- 🇺🇸
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Veterans Affairs Medical Center - Lakeside Chicago, Chicago, Illinois, United States
🇺🇸New England Medical Center Hospital, Boston, Massachusetts, United States
Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
- Conditions
- Interventions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00061958
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer
- Conditions
- First Posted Date
- 2003-05-21
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005999
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.